Equities research analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to report ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which would suggest a negative year over year growth rate of 18.2%. The business is expected to report its next earnings results on Wednesday, November 6th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.40). For the next financial year, analysts forecast that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Several large investors have recently added to or reduced their stakes in VKTX. BlackRock Inc. grew its position in shares of Viking Therapeutics by 22.4% in the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after buying an additional 749,505 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Viking Therapeutics by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after buying an additional 1,555 shares during the last quarter. Northern Trust Corp grew its position in shares of Viking Therapeutics by 18.5% in the 4th quarter. Northern Trust Corp now owns 728,958 shares of the biotechnology company’s stock worth $5,576,000 after buying an additional 113,995 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Viking Therapeutics in the 4th quarter worth approximately $1,478,000. Finally, Stifel Financial Corp grew its position in shares of Viking Therapeutics by 30.7% in the 4th quarter. Stifel Financial Corp now owns 22,314 shares of the biotechnology company’s stock worth $176,000 after buying an additional 5,237 shares during the last quarter. 63.96% of the stock is owned by institutional investors and hedge funds.
Shares of VKTX stock traded down $0.13 during trading hours on Friday, hitting $7.13. The company’s stock had a trading volume of 765,835 shares, compared to its average volume of 2,458,445. The stock has a 50 day simple moving average of $8.00. The stock has a market cap of $520.63 million, a PE ratio of -17.83 and a beta of 2.29. Viking Therapeutics has a 12-month low of $6.68 and a 12-month high of $24.00.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Further Reading: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.